160 related articles for article (PubMed ID: 11676228)
1. Effects of the combined hormonal replacement drug estradiol valerate/levonorgestrel on climacteric complaints, endometrium and lipid profile of peri- and postmenopausal women.
Georgiev DB; Golbs S; Goudev A
Methods Find Exp Clin Pharmacol; 2001 May; 23(4):197-202. PubMed ID: 11676228
[TBL] [Abstract][Full Text] [Related]
2. [Effect of combined conjugated estrogen-medrogestone replacement therapy on lipid profiles, climacteric symptoms and the endometrium].
Belaisch J; Nappi C; Affinito P; De Gezelle H; Botelho M; Oliveira HM; Martinez-Oliveira J; Gonzaga F
J Gynecol Obstet Biol Reprod (Paris); 2000 Feb; 29(1):29-40. PubMed ID: 10675831
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and tolerability of the hormone replacement drug estradiol valerate/levonorgestrel in the treatment of menopausal syndrome in Thai women.
Chittacharoen A; Domhardt R; Manonai J; Golbs S
Methods Find Exp Clin Pharmacol; 2003 Oct; 25(8):645-51. PubMed ID: 14671683
[TBL] [Abstract][Full Text] [Related]
4. Changes in normal lipid profile of menopausal women with combined hormone replacement therapy. Comparative clinical trial of two hormonal combinations (conjugated estrogens/medroxyprogesterone acetate versus estradiol valerate/cyproterone acetate).
Alwers R; Urdinola J; Onatra W; Sánchez F; Posso H
Maturitas; 1999 May; 32(1):41-50. PubMed ID: 10423715
[TBL] [Abstract][Full Text] [Related]
5. Transdermal estrogen with a levonorgestrel-releasing intrauterine device for climacteric complaints: clinical and endometrial responses.
Raudaskoski TH; Lahti EI; Kauppila AJ; Apaja-Sarkkinen MA; Laatikainen TJ
Am J Obstet Gynecol; 1995 Jan; 172(1 Pt 1):114-9. PubMed ID: 7847516
[TBL] [Abstract][Full Text] [Related]
6. Intrauterine 10 microg and 20 microg levonorgestrel systems in postmenopausal women receiving oral oestrogen replacement therapy: clinical, endometrial and metabolic response.
Raudaskoski T; Tapanainen J; Tomás E; Luotola H; Pekonen F; Ronni-Sivula H; Timonen H; Riphagen F; Laatikainen T
BJOG; 2002 Feb; 109(2):136-44. PubMed ID: 11888095
[TBL] [Abstract][Full Text] [Related]
7. Intrauterine administration of levonorgestrel in two low doses in HRT. A randomized clinical trial during one year: effects on lipid and lipoprotein metabolism.
Wollter-Svensson LO; Stadberg E; Andersson K; Mattsson LA; Odlind V; Persson I
Maturitas; 1995 Nov; 22(3):199-205. PubMed ID: 8746877
[TBL] [Abstract][Full Text] [Related]
8. Climodien (estradiol valerate 2 mg plus dienogest 2 mg) is safe and effective in the treatment of postmenopausal complaints.
Gräser T; Römer T; Wiedey KD; Janaud A
Climacteric; 2001 Dec; 4(4):332-42. PubMed ID: 11770190
[TBL] [Abstract][Full Text] [Related]
9. Effects of a lipid lowering fibrate and hormone replacement therapy on serum lipids and lipoproteins in overweight postmenopausal women with elevated triglycerides.
Nerbrand C; Nyberg P; Nordström L; Samsioe G
Maturitas; 2002 May; 42(1):55-62. PubMed ID: 12020980
[TBL] [Abstract][Full Text] [Related]
10. Influence of two hormone replacement therapy regimens, oral oestradiol valerate and cyproterone acetate versus transdermal oestradiol and oral dydrogesterone, on lipid metabolism.
Schram JH; Boerrigter PJ; The TY
Maturitas; 1995 Sep; 22(2):121-30. PubMed ID: 8538480
[TBL] [Abstract][Full Text] [Related]
11. Lipid effects of an intrauterine levonorgestrel device or oral vs. vaginal natural progesterone in post-menopausal women treated with percutaneous estradiol.
Suvanto-Luukkonen E; Sundström H; Penttinen J; Kauppila A
Arch Gynecol Obstet; 1998; 261(4):201-8. PubMed ID: 9789651
[TBL] [Abstract][Full Text] [Related]
12. A comparative study of two levonorgestrel-containing hormone replacement therapy regimens of efficacy and tolerability variables.
Gräser T; Rössner P; Schubert K; Müller A; Bönisch U; Oettel M
Maturitas; 1997 Dec; 28(2):169-79. PubMed ID: 9522325
[TBL] [Abstract][Full Text] [Related]
13. Two new combinations of estrogen and progestogen for prevention of postmenopausal bone loss: long-term effects on bone, calcium and lipid metabolism, climacteric symptoms, and bleeding.
Marslew U; Overgaard K; Riis BJ; Christiansen C
Obstet Gynecol; 1992 Feb; 79(2):202-10. PubMed ID: 1309944
[TBL] [Abstract][Full Text] [Related]
14. Clinical experience with a low-dose combination of estradiol valerate and levonorgestrel. Double-blind comparative study between SH D 386 F and Cyclabil. Effects on symptoms, lipids and endometrial condition.
Lagrelius A; Fredricsson B; Hirt M; Weintraub L
Acta Obstet Gynecol Scand Suppl; 1986; 134():97-101. PubMed ID: 3101396
[TBL] [Abstract][Full Text] [Related]
15. [Hormonal therapy in perimenopause].
Zaĭdieva IaZ
Akush Ginekol (Mosk); 1995; (3):28-30. PubMed ID: 7653724
[TBL] [Abstract][Full Text] [Related]
16. Effect of hormone replacement therapy on lipoprotein(a) and lipid levels in postmenopausal women. Influence of various progestogens and duration of therapy.
Kim CJ; Min YK; Ryu WS; Kwak JW; Ryoo UH
Arch Intern Med; 1996 Aug 12-26; 156(15):1693-700. PubMed ID: 8694668
[TBL] [Abstract][Full Text] [Related]
17. Transdermal estrogen with a levonorgestrel-releasing intrauterine device for climacteric complaints versus estradiol-releasing vaginal ring with a vaginal progesterone suppository: clinical and endometrial responses.
Antoniou G; Kalogirou D; Karakitsos P; Antoniou D; Kalogirou O; Giannikos L
Maturitas; 1997 Mar; 26(2):103-11. PubMed ID: 9089559
[TBL] [Abstract][Full Text] [Related]
18. Effects of endurance exercise and hormone replacement therapy on serum lipids in older women.
Binder EF; Birge SJ; Kohrt WM
J Am Geriatr Soc; 1996 Mar; 44(3):231-6. PubMed ID: 8600189
[TBL] [Abstract][Full Text] [Related]
19. The effects of estradiol valerate plus medroxyprogesterone acetate and conjugated estrogens plus medrogestone on climacteric symptoms and metabolic variables in perimenopausal women.
Egarter C; Geurts P; Boschitsch E; Speiser P; Huber J
Acta Obstet Gynecol Scand; 1996 Apr; 75(4):386-93. PubMed ID: 8638462
[TBL] [Abstract][Full Text] [Related]
20. HRT and exercise: effects on bone density, muscle strength and lipid metabolism. A placebo controlled 2-year prospective trial on two estrogen-progestin regimens in healthy postmenopausal women.
Heikkinen J; Kyllönen E; Kurttila-Matero E; Wilén-Rosenqvist G; Lankinen KS; Rita H; Väänänen HK
Maturitas; 1997 Mar; 26(2):139-49. PubMed ID: 9089564
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
